Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cooper

Showing results (261-270 of 319) with videos related to

Pageof 32
Sort By:
Health Technology Assessment (Winchester, England)|July 5, 2021
The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCTJane E Norman, John Norrie, Graeme MacLennan, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Journal of Virology|April 14, 2006
Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challengeRobert J Natuk, David Cooper, Min Guo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2024
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk ConditionsMatthew Davis, William Towner, Elliot DeHaan, et al.
Research Square|June 29, 2026
Precision RNAi for Fibrodysplasia Ossificans Progressiva: a combinatorial, unimolecular, allele selective approachJaeHyuck Shim, Yeon-Suk Yang, Katherine Gross, et al.
Lancet (London, England)|March 25, 2025
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trialMohamed Abdel-Fattah, Christopher Chapple, David Cooper, et al.
Health Technology Assessment (Winchester, England)|July 7, 2025
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluationMohamed Abdel-Fattah, Christopher Chapple, Suzanne Breeman, et al.
The New England Journal of Medicine|September 5, 2019
Five-Year Outcomes of a Randomized Trial of Treatments for Varicose VeinsJulie Brittenden, David Cooper, Maria Dimitrova, et al.
Vaccines|April 23, 2025
Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired AdultsNatalia Castillo Almeida, Lalitha Parameswaran, Elliot N DeHaan, et al.
Pageof 32

Showing results (261-270 of 319) with videos related to

Sort By:
Pageof 32
Health Technology Assessment (Winchester, England)|July 5, 2021
The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCTJane E Norman, John Norrie, Graeme MacLennan, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Journal of Virology|April 14, 2006
Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challengeRobert J Natuk, David Cooper, Min Guo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2024
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk ConditionsMatthew Davis, William Towner, Elliot DeHaan, et al.
Research Square|June 29, 2026
Precision RNAi for Fibrodysplasia Ossificans Progressiva: a combinatorial, unimolecular, allele selective approachJaeHyuck Shim, Yeon-Suk Yang, Katherine Gross, et al.
Lancet (London, England)|March 25, 2025
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trialMohamed Abdel-Fattah, Christopher Chapple, David Cooper, et al.
Health Technology Assessment (Winchester, England)|July 7, 2025
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluationMohamed Abdel-Fattah, Christopher Chapple, Suzanne Breeman, et al.
The New England Journal of Medicine|September 5, 2019
Five-Year Outcomes of a Randomized Trial of Treatments for Varicose VeinsJulie Brittenden, David Cooper, Maria Dimitrova, et al.
Vaccines|April 23, 2025
Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired AdultsNatalia Castillo Almeida, Lalitha Parameswaran, Elliot N DeHaan, et al.
Pageof 32